Parkinson’s Disease Clinical Trial

 

 

    RESTORE Phase 2 Trial of VY-AADC for Parkinson’s Disease

Voyager is beginning a Phase 2, placebo-controlled trial to assess its gene therapy program, VY-AADC, for the treatment of Parkinson’s disease. Twenty-four clinical trial sites (including neurosurgical and neurology patient referral sites) have been selected for participation in the Phase 2 trial.

For more information about Voyager’s RESTORE Phase 2 clinical trial with its gene therapy program VY-AADC for the treatment of Parkinson’s disease, please click here or email clinicaltrials@vygr.com.